PDF herunterladen
Aktuelle Rheumatologie 2002; 27(2): 90-96
DOI: 10.1055/s-2002-25725
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Das chronische Erschöpfbarkeitssyndrom (CFS)

The Chronic Fatigue Syndrome (CFS)M.  Späth1
  • 1Friedrich-Baur-Institut (Leitender Arzt: Prof. Dr. med. D. Pongratz), Ludwig-Maximilians-Universität München
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. April 2002 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Das chronische Erschöpfbarkeitssyndrom (CFS) ist ein Symptomenkomplex, der, einem Katalog von Klassifikationskriterien folgend, nach Ausschluss anderer, die chronische abnorme Erschöpfbarkeit evtl. erklärender Erkrankungen die Zuordnung des Beschwerdebildes zu einem CFS zulässt. Dieser „Rahmen” wurde zur Vereinheitlichung der Durchführung wissenschaftlicher Studien konzipiert. Solche Studien erbrachten bisher zahlreiche Hinweise auf mögliche Störungen der komplexen Interaktionen von HPA-Achse, Neurotransmittersystemen und Mediatoren des Immunsystems, jedoch keinen spezifischen diagnostischen Marker. Die bisherigen Forschungsergebnisse zu Ätiologie und Pathogenese werden ebenso referiert wie die Studien zu möglichen Therapieansätzen.

Abstract

Chronic fatigue syndrome (CFS) is an illness defined exclusively by a group of symptoms, according to a case definition developed under the leadership of the US Centers for Disease Control and Prevention (CDC). All of the symptoms are nonspecific and occurring in many illnesses. There are no biological markers or any results from other methods which provide a specific diagnostic test for clinical use. However, there is evidence from many studies that alterations within the complex network of HPA axis, neurotransmitter systems and mediators of the immune system play a crucial role for the pathogenesis of CFS. Both these findings and the therapeutic approaches are reviewed.

  • 1 Acheson E D. The clinical syndrome variously called benign myalgic encephalomyelitis, Iceland diseases and epidemic neuromyasthenia.  Am J Med. 1959;  26 569-595
    CrossrefPubMedGoogle Scholar
  • 2 Allain T J, Bearn J A, Coskeran P, Jones J, Checkley A, Butler J, Wessely S, Miell J P. Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome.  Biol Psychiatry. 1997;  41 567-573
    CrossrefPubMedGoogle Scholar
  • 3 Bakheit A M, Behan P O, Dinan T G, Gray C E, O’Keane V. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome.  BMJ (Clinical Research Ed.). 1992;  304 1010-1012
    CrossrefPubMedGoogle Scholar
  • 4 Bakheit A M, Behan P O, Watson W S, Morton J J. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome.  Acta Neurol Scand. 1993;  87 234-238
    PubMedGoogle Scholar
  • 5 Barnes P R, Taylor D J, Kemp G J, Radda G K. Skeletal muscle bioenergetics in the chronic fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1993;  56 679-683
    PubMedGoogle Scholar
  • 6 Beard G M. Neurasthenia or nervous exhaustion.  Boston Med Surg. 1869;  J III 217-221
    PubMedGoogle Scholar
  • 7 Bearn J, Allain T, Coskeran P, Munro N, Butler J, McGregor A, Wessely S. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome.  Biol Psychiatry. 1995;  37 245-252
    CrossrefPubMedGoogle Scholar
  • 8 Behan P O, Behan W M. Postviral fatigue syndrome.  Crit Rev Neurobiol. 1988;  4 157-178
    PubMedGoogle Scholar
  • 9 Behan P O, Behan W M, Gow J W, Cavanagh H, Gillespie S. Enteroviruses and postviral fatigue syndrome (discussion 154 - 149).  Ciba Found Symp. 1993;  173 146-154
    PubMedGoogle Scholar
  • 10 Behan P O, Behan W M, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome.  Acta Neurol Scand. 1990;  82 209-216
    PubMedGoogle Scholar
  • 11 Behan W M, More I A, Behan P O. Mitochondrial abnormalities in the postviral fatigue syndrome.  Acta Neuropathol (Berl). 1991;  83 61-65
    CrossrefPubMedGoogle Scholar
  • 12 Bennett A L, Fagioli L R, Schur P H, Schacterle R S, Komaroff A L. Immunoglobulin subclass levels in chronic fatigue syndrome.  J Clin Immunol. 1996;  16 315-320
    CrossrefPubMedGoogle Scholar
  • 13 Bennett A L, Mayes D M, Fagioli L R, Guerriero R, Komaroff A L. Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndrome.  J Psychiatr Res. 1997;  31 91-96
    CrossrefPubMedGoogle Scholar
  • 14 Brooks J C, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome.  Br J Radiol. 2000;  73 1206-1208
    PubMedGoogle Scholar
  • 15 Buchwald D, Ashley R L, Pearlman T, Kith P, Komaroff A L. Viral serologies in patients with chronic fatigue and chronic fatigue syndrome.  J Med Virol. 1996;  50 25-30
    CrossrefPubMedGoogle Scholar
  • 16 Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities.  Arch Intern Med. 1994;  154 2049-2053
    Google Scholar
  • 17 Buchwald D, Umali P, Umali J, Kith P, Pearlman T, Komaroff A L. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system.  Ann Intern Med. 1995;  123 81-88
    PubMedGoogle Scholar
  • 18 Buchwald D, Wener M H, Pearlman T, Kith P. Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome.  J Rheumatol. 1997;  24 372-376
    PubMedGoogle Scholar
  • 19 Butler S, Chalder T, Ron M, Wessely S. Cognitive behaviour therapy in chronic fatigue syndrome.  Journal Of Neurology, Neurosurgery And Psychiatry. 1991;  54 153-158
    PubMedGoogle Scholar
  • 20 Byrne E, Trounce I. Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.  J Neurol Neurosurg Psychiatry. 1987;  50 743-746
    PubMedGoogle Scholar
  • 21 Cleare A J, Bearn J, Allain T, McGregor A, Wessely S, Murray R M, O’Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome.  J Affect Disord. 1995;  34 283-289
    CrossrefPubMedGoogle Scholar
  • 22 Cleare A J, Heap E, Malhi G S, Wessely S, O’Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial.  Lancet. 1999;  353 455-458
    CrossrefPubMedGoogle Scholar
  • 23 Coyle P K, Krupp L B, Doscher C, Amin K. Borrelia burgdorferi reactivity in patients with severe persistent fatigue who are from a region in which Lyme disease is endemic.  Clin Infect Dis. 1994;  18 Suppl 1 S24-27
    PubMedGoogle Scholar
  • 24 Crofford L J. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome.  Z Rheumatol. 1998;  57 67-71
    CrossrefPubMedGoogle Scholar
  • 25 Crofford L J, Demitrack M A. Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome.  Rheum Dis Clin North Am. 1996;  22 267-284
    PubMedGoogle Scholar
  • 26 de Meirleir K, Bisbal C, Campine I, de Becker P, Salehzada T, Demettre E, Lebleu B. A 37 kDa 2 - 5A binding protein as a potential biochemical marker for chronic fatigue syndrome.  Am J Med. 2000;  108 99-105
    PubMedGoogle Scholar
  • 27 Deale A, Chalder T, Marks I, Wessely S. Cognitive behavior therapy for chronic fatigue syndrome: a randomized controlled trial.  Am J Psychiatry. 1997;  154 408-414
    PubMedGoogle Scholar
  • 28 Demitrack M A. Chronic fatigue syndrome and fibromyalgia. Dilemmas in diagnosis and clinical management.  Psychiatr Clin North Am. 1998;  21 671-692
    CrossrefPubMedGoogle Scholar
  • 29 Demitrack M A, Crofford L J. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome.  Ann N Y Acad Sci. 1998;  840 684-697
    PubMedGoogle Scholar
  • 30 Dismukes W E, Wade J S, Lee J Y, Dockery B K, Hain J D. A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome.  N Engl J Med. 1990;  323 1717-1723
    PubMedGoogle Scholar
  • 31 Dykman K D, Tone C, Ford C, Dykman R A. The effects of nutritional supplements on the symptoms of fibromyalgia and chronic fatigue syndrome.  Integr Physiol Behav Sci. 1998;  33 61-71
    PubMedGoogle Scholar
  • 32 Evengard B, Briese T, Lindh G, Lee S, Lipkin W I. Absence of evidence of Borna disease virus infection in Swedish patients with Chronic Fatigue Syndrome.  J Neurovirol. 1999;  5 495-499
    PubMedGoogle Scholar
  • 33 Fischler B, Le B on, Hoffmann G, Cluydts R, Kaufman L, de Meirleir K. Sleep anomalies in the chronic fatigue syndrome. A comorbidity study.  Neuropsychobiology. 1997;  35 115-122
    PubMedGoogle Scholar
  • 34 Fukuda K, Straus S E, Hickie I, Sharpe M C, Dobbins J G, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.  Annals Intern Med. 1994;  121 953-959
    Google Scholar
  • 35 Goodnick P J, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders.  J Clin Psychiatry. 1993;  54 13-20
    PubMedGoogle Scholar
  • 36 Gow J W, Behan W M, Simpson K, McGarry F, Keir S, Behan P O. Studies on enterovirus in patients with chronic fatigue syndrome.  Clin Infect Dis. 1994;  18 Suppl 1 126-129
    PubMedGoogle Scholar
  • 37 Gray J B, Martinovic A M. Eicosanoids and essential fatty acid modulation in chronic disease and the chronic fatigue syndrome published erratum appears in Med Hypotheses 1995 Aug;45(2): 219.  Medical Hypotheses. 1994;  43 31-42
    CrossrefPubMedGoogle Scholar
  • 38 Holmes G P, Kaplan J E, Gantz N M, Komaroff A L, Schonberger L B, Straus S E, Jones J F, Dubois R E, Cunningham-Rundles C, Pahwa S. et al . Chronic fatigue syndrome: a working case definition.  Ann Intern Med. 1988;  108 387-389
    PubMedGoogle Scholar
  • 39 Ichise M, Salit I E, Abbey S E, Chung D G, Gray B, Kirsh J C, Freedman M. Assessment of regional cerebral perfusion by 99Tcm-HMPAO SPECT in chronic fatigue syndrome.  Nucl Med Commun. 1992;  13 767-772
    PubMedGoogle Scholar
  • 40 Jones J F, Ray C G, Minnich L L, Hicks M J, Kibler R, Lucas D O. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies.  Ann Intern Med. 1985;  102 1-7
    PubMedGoogle Scholar
  • 41 Kent-Braun J A. Central and peripheral contributions to muscle fatigue in humans during sustained maximal effort.  Eur J Appl Physiol Occup Physiol. 1999;  80 57-63
    CrossrefPubMedGoogle Scholar
  • 42 Kent-Braun J A, Sharma K R, Weiner M W, Massie B, Miller R G. Central basis of muscle fatigue in chronic fatigue syndrome.  Neurology. 1993;  43 125-131
    PubMedGoogle Scholar
  • 43 Komaroff A L. The biology of chronic fatigue syndrome.  Am J Med. 2000;  108 169-171
    CrossrefPubMedGoogle Scholar
  • 44 Landay A L, Jessop C, Lennette E T, Levy J A. Chronic fatigue syndrome: clinical condition associated with immune activation.  Lancet. 1991;  338 707-712
    CrossrefPubMedGoogle Scholar
  • 45 Lawrie S M, Manders D N, Geddes J R, Pelosi A J. A population-based incidence study of chronic fatigue.  Psychol Med. 1997;  27 343-353
    CrossrefPubMedGoogle Scholar
  • 46 Lawrie S M, Pelosi A J. Chronic fatigue syndrome in the community. Prevalence and associations.  Br J Psychiatry. 1995;  166 793-797
    PubMedGoogle Scholar
  • 47 Le B on, Hoffmann G, Murphy J, de Meirleir K, Cluydts R, Pelc I. How significant are primary sleep disorders and sleepiness in the chronic fatigue syndrome?.  Sleep Res Online. 2000;  3 43-48
    PubMedGoogle Scholar
  • 48 Lindh G, Samuelson A, Hedlund K O, Evengard B, Lindquist L, Ehrnst A. No findings of enteroviruses in Swedish patients with chronic fatigue syndrome.  Scand J Infect Dis. 1996;  28 305-307
    CrossrefPubMedGoogle Scholar
  • 49 Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.  Am J Med. 1990;  89 561-568
    CrossrefPubMedGoogle Scholar
  • 50 Lloyd A R, Hickie I, Boughton C R, Spencer O, Wakefield D. Prevalence of chronic fatigue syndrome in an Australian population.  Med J Aust. 1990;  153 522-528
    PubMedGoogle Scholar
  • 51 Manian F A. Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus types 1 and 2, and 14 enteroviruses in chronic fatigue syndrome: is there evidence of activation of a nonspecific polyclonal immune response?.  Clin Infect Dis. 1994;  19 448-453
    PubMedGoogle Scholar
  • 52 Manu P, Lane T J, Matthews D A, Castriotta R J, Watson R K, Abeles M. Alpha-delta sleep in patients with a chief complaint of chronic fatigue.  South Med J. 1994;  87 465-470
    PubMedGoogle Scholar
  • 53 Mawle A C, Nisenbaum R, Dobbins J G, Gary H E, Jr. , Stewart J A, Reyes M, Steele L, Schmid D S, Reeves W C. Immune responses associated with chronic fatigue syndrome: a case-control study.  J Infect Dis. 1997;  175 136-141
    PubMedGoogle Scholar
  • 54 Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome.  Ciba Found Symp. 1993;  173 262-271
    PubMedGoogle Scholar
  • 55 Nakaya T, Takahashi H, Nakamur Y, Kuratsune H, Kitani T, Machii T, Yamanishi K, Ikuta K. Borna disease virus infection in two family clusters of patients with chronic fatigue syndrome.  Microbiol Immunol. 1999;  43 679-689
    PubMedGoogle Scholar
  • 56 Neeck G, Crofford L J. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome.  Rheum Dis Clin North Am. 2000;  26 989-1002
    PubMedGoogle Scholar
  • 57 Nix W A, Egle U T. Das chronische Erschöpfbarkeitssyndrom.  Akt Neurologie. 1998;  25 6-12
    PubMedGoogle Scholar
  • 58 Norregaard J, Bulow P M, Prescott E, Jacobsen S, Danneskiold-Samsoe B. A four-year follow-up study in fibromyalgia. Relationship to chronic fatigue syndrome.  Scand J Rheumatol. 1993;  22 35-38
    PubMedGoogle Scholar
  • 59 Parker A J, Wessely S, Cleare A J. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia.  Psychol Med. 2001;  31 1331-1345
    PubMedGoogle Scholar
  • 60 Peakman M, Deale A, Field R, Mahalingam M, Wessely S. Clinical improvement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation.  Clin Immunol Immunopathol. 1997;  82 83-91
    CrossrefPubMedGoogle Scholar
  • 61 Peterson P K, Pheley A, Schroeppel J, Schenck C, Marshall P, Kind A, Haugland J M, Lambrecht L J, Swan S, Goldsmith S. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome.  Arch Intern Med. 1998;  158 908-914
    CrossrefPubMedGoogle Scholar
  • 62 Peterson P K, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, Lurie N. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome.  Am J Med. 1990;  89 554-560
    CrossrefPubMedGoogle Scholar
  • 63 Plioplys A V, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome.  Neuropsychobiology. 1997;  35 16-23
    PubMedGoogle Scholar
  • 64 Preedy V R, Smith D G, Salisbury J R, Peters T J. Biochemical and muscle studies in patients with acute onset post-viral fatigue syndrome.  J Clin Pathol. 1993;  46 722-726
    PubMedGoogle Scholar
  • 65 Price J R, Couper J. Cognitive behaviour therapy for adults with chronic fatigue syndrome.  Cochrane Database Syst Rev. 2000;  CD 001 027
    PubMedGoogle Scholar
  • 66 Prins J B, Bleijenberg G, Bazelmans E, Elving L D, de Boo T M, Severens J L, van der Wilt G J, Spinhoven P, van der Meer J W. Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial.  Lancet. 2001;  357 841-847
    CrossrefPubMedGoogle Scholar
  • 67 Reeves W C, Stamey F R, Black J B, Mawle A C, Stewart J A, Pellett P E. Human herpesviruses 6 and 7 in chronic fatigue syndrome: a case-control study.  Clin Infect Dis. 2000;  31 48-52
    CrossrefPubMedGoogle Scholar
  • 68 Rowe P C, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, Cuccherini B A, Soto N, Hohman P, Snader S, Lucas K E, Wolff M, Straus S E. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial.  Jama. 2001;  285 52-59
    CrossrefPubMedGoogle Scholar
  • 69 Schutzer S E, Natelson B H. Absence of Borrelia burgdorferi-specific immune complexes in chronic fatigue syndrome.  Neurology. 1999;  53 1340-1341
    PubMedGoogle Scholar
  • 70 Schwartz R B, Komaroff A L, Garada B M, Gleit M, Doolittle T H, Bates D W, Vasile R G, Holman B L. SPECT imaging of the brain: comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression.  AJR. 1994;  162 943-951
    PubMedGoogle Scholar
  • 71 Sharpe M, Clements A, Hawton K, Young A H, Sargent P, Cowen P J. Increased prolactin response to buspirone in chronic fatigue syndrome.  Journal Of Affective Disorders. 1996;  41 71-76
    CrossrefPubMedGoogle Scholar
  • 72 Sharpe M, Hawton K, Clements A, Cowen P J. Increased brain serotonin function in men with chronic fatigue syndrome.  BMJ (Clinical Research Ed.). 1997;  315 164-165
    PubMedGoogle Scholar
  • 73 Sharpe M C, Archard L C, Banatvala J E, Borysiewicz L K, Clare A W, David A, Edwards R H, Hawton K E, Lambert H P, Lane R J. et al . A report-chronic fatigue syndrome: guidelines for research.  J R Soc Med. 1991;  84 118-121
    PubMedGoogle Scholar
  • 74 Spaeth M, Stratz T, Schmalisch P, Mueller W, Pongratz D. Carnitine deficiency and fibromyalgia.  Arthritis Rheum. 1999;  42 150
    PubMedGoogle Scholar
  • 75 Späth M, Welzel D, Farber L. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists-preliminary results.  Scand J Rheumatol Suppl. 2000;  113 72-77
    PubMedGoogle Scholar
  • 76 Straus S E, Dale J K, Peter J B, Dinarello C A. Circulating lymphokine levels in the chronic fatigue syndrome.  J Infect Dis. 1989;  160 1085-1086
    PubMedGoogle Scholar
  • 77 Straus S E, Dale J K, Tobi M, Lawley T, Preble O, Blaese R M, Hallahan C, Henle W. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial.  N Engl J Med. 1988;  319 1692-1698
    PubMedGoogle Scholar
  • 78 Suhadolnik R J, Peterson D L, O’Brien K, Cheney P R, Herst C V, Reichenbach N L, Kon N, Horvath S E, Iacono K T, Adelson M E, de Meirleir K, de Becker P, Charubala R, Pfleiderer W. Biochemical evidence for a novel low molecular weight 2 - 5A-dependent RNase L in chronic fatigue syndrome.  J Interferon Cytokine Res. 1997;  17 377-385
    CrossrefPubMedGoogle Scholar
  • 79 Swanink C M, van der Meer J W, Vercoulen J H, Bleijenberg G, Fennis J F, Galama J M. Epstein-Barr virus (EBV) and the chronic fatigue syndrome: normal virus load in blood and normal immunologic reactivity in the EBV regression assay.  Clin Infect Dis. 1995;  20 1390-1392
    PubMedGoogle Scholar
  • 80 Swanink C M, Vercoulen J H, Bleijenberg G, Fennis J F, Galama J M, van der Meer J W. Chronic fatigue syndrome: a clinical and laboratory study with a well matched control group.  J Intern Med. 1995;  237 499-506
    PubMedGoogle Scholar
  • 81 Tobi M, Morag A, Ravid Z, Chowers I, Feldman-Weiss V, Michaeli Y, Ben-Chetrit E, Shalit M, Knobler H. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection.  Lancet. 1982;  1 61-64
    PubMedGoogle Scholar
  • 82 Vercoulen J H, Swanink C M, Zitman F G, Vreden S G, Hoofs M P, Fennis J F, Galama J M, van der Meer J W, Bleijenberg G. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.  Lancet. 1996;  347 858-861
    CrossrefPubMedGoogle Scholar
  • 83 Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, Lloyd A. Intravenous immunoglobulin is ineffective in the treatment of patients with chronic fatigue syndrome.  Am J Med. 1997;  103 38-43
    CrossrefPubMedGoogle Scholar
  • 84 Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study.  Am J Public Health. 1997;  87 1449-1455
    CrossrefPubMedGoogle Scholar
  • 85 Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many ?.  Lancet. 1999;  354 936-939
    CrossrefPubMedGoogle Scholar
  • 86 Wessely S, Powell R. Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders.  J Neurol Neurosurg Psychiatry. 1989;  52 940-948
    CrossrefPubMedGoogle Scholar
  • 87 Whiting P, Bagnall A M, Sowden A J, Cornell J E, Mulrow C D, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.  Jama. 2001;  286 1360-1368
    CrossrefPubMedGoogle Scholar

Dr. med. M. Späth

Friedrich-Baur-Institut · Universität München

Ziemssenstraße 1a · 80336 München ·

Telefon: 089/5160-7420

Fax: 089/5160-7422

eMail: Michael.Spaeth@lrz.uni-muenchen.de

      >